Catalin Bobirca/LinkedIn
Jun 16, 2026, 14:36
Catalin Bobirca: EHA 2026 Showcases the Future of Hemoglobinopathies Care
Catalin Bobirca, Director of Global Medical Affairs Hemoglobinopathies at Novo Nordisk, shared a post on LinkedIn:
“Back from EHA 2026 and feeling incredibly inspired!
The updates in hemoglobinopathies research highlight just how far we’ve come—and where the future of medicine is heading.
Beyond the data, the highlight of my week was connecting (and reconnecting) with so many dedicated physicians and peers.
Thank you for the insightful discussions and your shared commitment to transforming patient lives.
Let’s stay connected!
One special thanks to the team that made all this possible!”
Stay updated with Hemostasis Today.
-
Jun 16, 2026, 14:30Jeffrey Kallberg: Education and Advocacy at the Texas Bleeding Disorders Conference
-
Jun 16, 2026, 14:23Alfadil Haroon: Bleeding Outcomes in Congenital Versus Acquired FXIII Deficiency
-
Jun 16, 2026, 14:20Matthew James: Anticoagulation Errors – 5 Prescribing Red Flags That Lead to Bleeding
-
Jun 16, 2026, 14:13Miguel Crato: Pleased to Share the Farewell Speech Closing My Chapter as President of the EHC
-
Jun 16, 2026, 14:09Abdul Mannan: Antiphospholipid Syndrome in Thrombotic Storm Mode
-
Jun 16, 2026, 14:06Harshal Kale: Connecting for Greater Impact at the Rotary International Conference
-
Jun 16, 2026, 14:04Tara Lech: Join the Movement Toward Better Anticoagulation Care
-
Jun 16, 2026, 13:56Christina (Tina) P.: Can Vitamin K Help Stabilize Your INR?
-
Jun 16, 2026, 13:49Tomáš Šimurda: Fibromics Team Secures EHA Innovation Grant for Innovative Research